Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

54.92 -2.14 (-3.75%)

Delayed Quote Updated: 4:00 PM EST, Nov 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

NASDAQ:GMAB qualifies as a high growth stock and is consolidating. ↗

October 09, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

NASDAQ:GMAB is an undervalued gem with solid fundamentals. ↗

October 08, 2024

Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—it's a hidden gem with strong fundamentals and an attractive price tag.

Via Chartmill

NASDAQ:GMAB, a growth stock which is not overvalued. ↗

October 07, 2024

NASDAQ:GMAB is showing good growth, while it is not too expensive.

Via Chartmill

Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

September 23, 2024

Via Benzinga

NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying. ↗

September 17, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) is an undervalued gem with solid fundamentals.

Via Chartmill

Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. ↗

September 16, 2024

Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

Expert Ratings For Genmab ↗

September 09, 2024

Via Benzinga

NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗

September 03, 2024

Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

NASDAQ:GMAB is showing good growth, while it is not too expensive. ↗

August 26, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) is not too expensive for the growth it is showing.

Via Chartmill

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

September 15, 2024

From Genmab A/S

Via Business Wire

Decoding 10 Analyst Evaluations For Genmab ↗

August 20, 2024

Via Benzinga

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

August 19, 2024

From Genmab A/S

Via Business Wire

Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock? ↗

August 05, 2024

Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

What 8 Analyst Ratings Have To Say About Genmab ↗

August 01, 2024

Via Benzinga

What 8 Analyst Ratings Have To Say About Genmab ↗

July 15, 2024

Via Benzinga

Genmab Announces Changes to its Executive Committee

August 16, 2024

From Genmab A/S

Via Business Wire

On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session ↗

August 13, 2024

Via Benzinga

GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

GMAB stock results show that Genmab missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products ↗

August 05, 2024

BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology...

Via Benzinga

NASDAQ:GMAB, an undervalued stock with good fundamentals. ↗

July 01, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

10 Analysts Assess Genmab: What You Need To Know ↗

June 20, 2024

Via Benzinga

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. ↗

August 05, 2024

While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.

Via Chartmill

Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. ↗

July 15, 2024

GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably.

Via Chartmill

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

June 28, 2024

From Genmab A/S

Via Business Wire

AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway ↗

June 27, 2024

The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy.

Via Benzinga

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

June 26, 2024

From Genmab A/S

Via Business Wire

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

Despite its growth, NASDAQ:GMAB remains within the realm of affordability. ↗

June 21, 2024

Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

7 Stocks That Could Safely 10X by 2030 ↗

June 06, 2024

Unlock the potential for exponential growth with these seven 10x stocks that could skyrocket by 2030 if the stars align.

Via InvestorPlace

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

June 03, 2024

From Genmab A/S

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.